Stockreport

Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases

Mirum Pharmaceuticals, Inc. - common stock  (MIRM) 
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
PDF - Study designed to support potential label expansion into additional settings of cholestatic pruritus- Topline data expected in Q4 2026 FOSTER CITY, Calif.--(BUSINES [Read more]